Puma Biotechnology Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (30)

Latest Posts

About This Stock More About This Stock
E Research Report: PBYI
Article By: Elle Investments
Friday, May 24, 2019 1:41 PM EDT
The lowered 2019 Nerlynx net sales guidance after 1Q19 results puts previous peak sales estimates of $1B+ in doubt. However, given the large sell-off, even with much lower peak sales estimates in the $500M+ range, there is still a lot of upside.
In this article: PBYI
Read
Puma Biotechnology: A Favorable Risk/Reward Bet
Article By: Elle Investments
Thursday, April 11, 2019 2:31 PM EDT
PBYI dropped about 8% when the EU/Africa licensing deal with Pierre Fabre was announced for potential blockbuster candidate Nerlynx, which is currently approved in the US and EU for HER2+ breast cancer treatment (post-Herceptin).
In this article: PBYI
Read
Puma Biotech: Is It Time For This Kitty To Roar?
Article By: TipRanks
Wednesday, October 10, 2018 10:29 PM EDT
Puma is an oncology company with drug Nerlynx approved for HER2 positive adjuvant breast cancer. But the market has yet to appreciate the drug’s full potential.
In this article: PBYI
Read
Week In Review: C-Bridge Raising Another $650 Million For China Healthcare
Article By: ChinaBio® Today
Saturday, February 3, 2018 4:43 PM EDT
Shanghai's C-Bridge Capital is raising capital for its third healthcare private equity fund with a target of $650 million (see story). Just six months ago, C-Bridge closed its second PE fund at a hard cap of $400 million.
In this article: CASI, SRNE, PBYI
Read
4 Biotech Stocks That More Than Doubled This Year
Article By: Zacks Investment Research
Saturday, December 23, 2017 7:50 PM EDT
The biotech industry has been on the comeback trail in 2017 after facing challenges including pricing pressure, rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for key drugs.
In this article: JUNO, BLUE, XOMA, PBYI, PIRS, ALNY Also: CELG
Read

PARTNER HEADLINES

Latest Tweets for $PBYI

No tweets yet!